SAN FRANCISCO, Jan. 12, 2026 — Leads & Copy — Counterpart Health, Inc., a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), has released its key highlights for 2025, showcasing the impact of its AI-powered physician-enablement platform. The year was marked by research publication, product expansion, and the scaled adoption of Counterpart Assistant (CA) by hundreds of third-party customer clinicians across various practice settings.
Data released in 2025 emphasizes the platform’s impact, reflecting improved clinical decisions during patient visits.
Clinical adoption saw a year-over-year increase of over 450% in live third-party customer clinicians. Returning Clover Health members whose primary care physicians (PCPs) use CA demonstrated an approximate 1,500 basis point MCR differential compared to those whose PCPs do not. Counterpart’s technology supported the #1 HEDIS score nationwide for a PPO Medicare Advantage plan for the second consecutive year across a wide network of non-employed physicians without capitation.
Throughout 2025, Counterpart released three retrospective data analyses validating CA’s ability to improve chronic disease management by equipping PCPs at the point-of-care:
Data indicated that new members were 75% more likely to be diagnosed with COPD in their first year when under the care of a CA PCP. COPD patients recorded an 18% higher average number of outpatient pulmonology visits, reflecting better coordination of specialty care.
Research showed that a relationship with a CA PCP was associated with an 18% lower rate of all-cause hospitalizations for Congestive Heart Failure (CHF) and a 15% lower rate for COPD. The studies also recorded meaningful reductions in 30-day readmissions (25% lower for CHF; 18% lower for COPD).
Data demonstrated how CA supports PCPs in resource-constrained, high Area Deprivation Index (ADI) neighborhoods. In these settings, CA attribution was associated with 70–89% higher diagnosis rates across four major chronic diseases, with patients identified at significantly earlier clinical stages.
In 2025, Counterpart expanded beyond the point of care to support clinicians and organizations across the full arc of care, marking its transition into an end-to-end clinical operating system for value-based care:
A fully integrated solution that listens to visits in real time, allowing physicians to focus on patients and bringing enterprise-grade technology to every practice.
Next-generation capabilities that allow clinicians to ask questions about a patient’s medical history in natural language and receive immediate responses and source documents, all within a PHI-safe environment.
Automated synthesis of longitudinal data that flags potential care opportunities before clinicians enter the exam room.
Expanded capabilities across quality operations, population health, and data services.
Conrad Wai, CEO of Counterpart Health, stated that better outcomes and lower costs are driven by improved clinical decisions made during patient visits. He added that the focus is on building a clinical operating system that works for any clinician, setting a new standard for care delivery.
Counterpart Health’s latest video highlights how each detected condition and prescription shapes a patient’s life, leading to earlier diagnoses, better management, and healthier lives.
Counterpart Health, a subsidiary of Clover Health Investments, Corp., is an AI-powered physician enablement platform that transforms care delivery. Counterpart Assistant, its flagship software, offers clinically intuitive insights to help clinicians manage chronic conditions and deliver high-quality care. Studies demonstrate the technology’s impact on managing Diabetes, Chronic Kidney Disease, Congestive Heart Failure, and Chronic Obstructive Pulmonary Disease, as well as Clinical Quality.
Investor Relations:
Ryan Schmidt
investors@cloverhealth.com
Press Inquiries:
press@cloverhealth.com
Source: Counterpart Health
